Michelle Callahan Buccini, USPTO Patent Examiner

Listed by the USPTO as BUCCINI, MICHELLE CALLAHAN

Tech Center 1600 • Art Units: 1643 1654 1675 1682

This examiner grants 0% of resolved cases

Performance Statistics

—

Allow Rate

-60.0% vs TC avg

Total Applications

—

Interview Lift

Avg Prosecution Days

Based on 0 resolved cases, 2023–2026

§101 Eligibility

21.4%

§102 Novelty

28.6%

§103 Obviousness

30.4%

§112 Clarity

App #	Title	Status	Assignee
18240201	DIAGNOSIS AND TREATMENT OF PRIMARY GRAFT DYSFUNCTION FOLLOWING LUNG TRANSPLANT	Final Rejection	Northwestern University
18580302	ALPHA-HEMOLYSIN VARIANTS FORMING NARROW CHANNEL PORES AND USES THEREOF	Non-Final OA	Roche Sequencing Solutions, Inc.
18006212	Precision Targeted Retromer Therapeutics for the Treatment of Neurodegenerative Diseases and Disorders	Non-Final OA	The Trustees of Columbia University in the City of New York

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Michelle Callahan Buccini examines applications in Art Unit 1643 in Tech Center 1600 (Biotechnology & Pharmaceuticals).